About Icagen

Advancing Ion Channels for Broad Discoveries

As a leader in ion channel drug discovery, Icagen has deep experience in advancing ion channel drug discovery programs alone and in collaboration with pharmaceutical and biotech partners. Icagen’s Ion Channel Technology platform allows progression of challenging ion channel targets by combining novel reagent generation, advanced biophysical analysis and cutting-edge applications of in silico drug discovery tools. The company also has similar depth for certain classes of transporter targets.

Through the acquisition of Icagen core assets, Ligand Pharmaceuticals Incorporated now benefits from the synergy that exists between Icagen’s Ion Channel Technology and other Ligand-owned technology platforms including the OmniAb® antibody discovery platform. Additionally, Icagen’s unique XRpro® technology, developed through refinements of X-ray fluorescence, advances ion channel and transporter drug discovery and development.

Key Advancement, Big Success

Icagen has extensive biological capabilities focused on ion channels and transporters, and decades of experience in novel drug discovery from screening to lead optimization. Icagen technologies target challenging indications with significant unmet medical need.

Icagen’s proprietary Ion Channel Technology enables pharmaceutical and biotech partners to solve challenges, specifically within neuroscience, cystic fibrosis, chronic kidney disease and more. Together we strive to bring meaningful new medicines to patients as quickly as possible.

Discover Our Technology

Driving New Discoveries

Icagen’s team of scientists and experts offer more than a century of combined pharmaceutical and biotech experience advancing ion channel science. With experience spanning the globe, we are a leader in partnering with other scientists to drive drug discovery and advance therapeutic programs.

Discover Our Leadership